Abstract
Objective.This study investigated the expression of vascular endothelial growth factor (VEGF) and topoisomerase IIα (TPIIα) in a cohort of serous ovarian carcinomas by immunohistochemistry with regard to outcome and clinicopathologic variables. Methods.Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas and 41 serous ovarian carcinomas were immunostained with antibodies to VEGF and TPIIα. Immunostaining for VEGF was scored with regard to quantity and intensity of positively stained cells as weak, focal strong, and diffuse strong. TPIIα labeling indices (LI) were quantitated as the percentage of positively stained nuclei in 1000 tumor cells. Results.VEGF expression was weak or negative in serous cystadenomas. In contrast, focal or diffuse strong immunostaining was observed in 21 cases (51%) of serous carcinomas. VEGF immunoreactivity was positively related with TPIIα LI (P = 0.0055), adverse outcome (P = 0.0052), high International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.0158), and high tumor grade (P = 0.0303). TPIIα LI increased with FIGO stage (P = 0.0076) as well as tumor grade (P = 0.0034) and indicated poor prognosis (P = 0.0182). Conclusions.VEGF immunoreactivity is related with TPIIα LI and prognostically relevant. Expression of VEGF protein and TPIIα may serve as markers of aggressive tumor behavior in serous adenocarcinomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
